| Methods |
Randomised controlled trial
Number of centres: number not stated
Location: not stated
Years: September 1995 ‐ April 2002
Sponsorship: not stated
Central pathology review: not stated
Definition of Complete Response: not stated |
| Participants |
Number of patients randomised: 116
Our analysis: 108
Patients untreated: yes
INCLUDED:
Histology: large cell lymphoma (diffuse, follicular, anaplastic), peripheral T‐cell lymphoma, and high risk clinical presentation tumour score > 2 (bulky mass, high ß2‐microglobulin, B‐symptoms, stage IV, high LDH, extranodal sites, primary mediastinal presentation)
IPI: not stated
Age: up to 60 years |
| Interventions |
Control group: 9 cycles of three alternating chemotherapy regimens (ATT), and replacing doxorubicin with idarubicin
Experimental group: 2 cycles of ATT, followed by two intensified chemotherapy cycles , followed by BEAM and ASCT |
| Outcomes |
Overall survival, Failure‐free survival, Response rates |
| Notes |
source: abstract |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
